Corbus Pharmaceutical Holdings, Inc. Securities Litigation
On or around 08/02/2019 (Notice of voluntarily dismissal)
Filing Date: March 12, 2019
According to the Complaint, Corbus purports to be a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases.
The Complaint alleges that during the Class Period, and unbeknownst to investors, Corbus made false and/or misleading statements and/or failed to disclose that Corbus’ drug candidate, Lenabasum, had “failed its major trials in [systemic sclerosis] and [cystic fibrosis].”
On June 3, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel.
This case was voluntarily dismissed on August 2, 2019.
Company & Securities Information
Defendant: Corbus Pharmaceutical Holdings, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: CRBP
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Carmen Kempf, et al. v. Corbus Pharmaceutical Holdings, Inc., et al.